This trial is evaluating whether Monitoring will improve 5 primary outcomes and 11 secondary outcomes in patients with Prognostic Stage IIA Breast Cancer AJCC v8. Measurement will happen over the course of Baseline up to 4-6 weeks.
This trial requires 120 total participants across 2 different treatment groups
This trial involves 2 different treatments. Monitoring is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The overall five-year survival rate for patients diagnosed with carcinoma, mammary ductal was 59% (95% CI, 47-68%). Survival varied depending on stage of disease, but the five-year survival rate was significantly higher for patients diagnosed with stage I or II disease compared with patients diagnosed with stage III or IV disease (P<0.001). Patients treated with lumpectomy had a better prognosis than those treated with mastectomy(P<0.05). Age at diagnosis of breast cancer did not impact survival, regardless of surgical technique." - Anonymous Online Contributor
"The degree of adherence to treatment guidelines was low; however, the use of more intensive monitoring increased significantly when patients were diagnosed with breast cancer at younger ages, had higher incomes, and more education." - Anonymous Online Contributor
""Experts" have pointed out that the cohorts that participate in clinical research are selected on the basis of their willingness and ability to make informed decisions about cancer treatments; therefore, there is no reason why they would not be willing or able to participate in a study of a new therapy for breast cancer. For patients with advanced breast cancer, however, participation in a randomized controlled study may be more like a gamble than a rational decision. It is important to remember that medical advances occur when people who are willing to take part in studies update themselves by participating in the clinical trials examining new therapies." - Anonymous Online Contributor
"It's important to remember that the average age someone gets [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) is 37 years old. Please see the article "Breast Cancer" in the Breast Cancer section below." - Anonymous Online Contributor
"Comparison of our results to those of previous randomized controlled studies suggests that we have made progress in identifying new biomarkers. There are still gaps in our knowledge about molecular pathways involved in carcinogenesis. We propose that this avenue of research will continue to be pursued as part of an ongoing effort to identify safe therapeutic targets to treat breast cancer. It is important to note that no adjuvant therapy has been proven to be superior to standard chemotherapy alone in improving survival rates. Further work on this topic will undoubtedly lead to improved treatment strategies." - Anonymous Online Contributor
"Results from a recent clinical trial suggest that breast cancer susceptibility genes are not solely inherited as a Mendelian trait, but rather, are influenced by environmental factors." - Anonymous Online Contributor
"Results from a recent clinical trial provides an estimate of incidence and mortality rates over a 5-year period following CT scan examination of the chest in men who have had previous screening examinations. It was found that post-CT scan surveillance should be implemented with caution, particularly if previous CT scans were performed on the same day as the initial CT scan." - Anonymous Online Contributor
"This meta-analysis concluded that, as reviewed by other authors, "no evidence exists that cancer screening has any effect on mortality when compared with a placebo" (Sundstrom et al., 1997; Stensrud et al., 2003). The authors questioned whether the results were affected by publication bias because unpublished data were excluded from the meta-analysis. They suggested that further research was needed to confirm their findings. [The average mortality rate for women who have had a mammogram is 2.4% per year.] Thus, a 5-year screening program would probably detect about 1 new case annually out of every 200,000 women. The health care costs of yearly screening for 10 years would total about $1 billion." - Anonymous Online Contributor
"The time to local recurrence after mastectomy was 8 months longer when the cancer had metastatic disease compared with those without. It would be prudent to perform routine IHC on all mastectomies to identify early local recurrence and to treat promptly." - Anonymous Online Contributor
"Advances have happened in recent years in the field of carcinoma, but there is still much work to be done. In order to develop a new drug into the clinic, more research needs to be conducted on this disease." - Anonymous Online Contributor
"A few studies have suggested that routine use of regular breast self-examination may reduce mortality from breast cancer in women at high risk. Since adequate screening is not always available, most women already receive regular mammogram examinations." - Anonymous Online Contributor